Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond
about
FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal CarcinomaExpression of EGFR Is Closely Related to Reduced 3-Year Survival Rate in Chinese Female NSCLCResectable left lower lobe non-small cell lung cancer with lymph node metastasis is related to unfavorable outcomes.Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.Wnt signaling as potential therapeutic target in lung cancer.Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.Survival and prognostic factors of non-small cell lung cancer patients with postoperative locoregional recurrence treated with radical radiotherapy.Molecular insights: Suppression of EGFR and AKT activation by a small molecule in non-small cell lung cancer.ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non-small cell lung cancer.Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.
P2860
Q35837391-1A6574BC-7FBB-4DC1-90FA-51917E152682Q36010179-12472AD0-F634-492D-8C11-F36E9F092CBBQ36439723-74611E69-2076-4F3A-82A7-39112F4F8C9EQ36715107-9DE43EE3-CF2E-4A40-9DBF-003887EDD0AAQ38735754-F69A6315-7FED-41FB-BD39-FFAA3F457BF4Q38899873-CB96DC95-6430-4088-BCFA-7F9E830924ACQ47099923-ABA01B47-32E9-490F-9A3B-8A496B249EF4Q47130055-B8B4B67E-0DB7-4421-854E-3550F60E9227Q47375003-8A5795E4-DFDE-4186-80AE-30EC47AFA005Q49657822-B0CEF7DA-7DA4-43E9-BDB8-AF880DEE2B94
P2860
Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pharmacogenomics of EGFR-targe ...... l lung cancer: EGFR and beyond
@ast
Pharmacogenomics of EGFR-targe ...... l lung cancer: EGFR and beyond
@en
Pharmacogenomics of EGFR-targe ...... l lung cancer: EGFR and beyond
@nl
type
label
Pharmacogenomics of EGFR-targe ...... l lung cancer: EGFR and beyond
@ast
Pharmacogenomics of EGFR-targe ...... l lung cancer: EGFR and beyond
@en
Pharmacogenomics of EGFR-targe ...... l lung cancer: EGFR and beyond
@nl
prefLabel
Pharmacogenomics of EGFR-targe ...... l lung cancer: EGFR and beyond
@ast
Pharmacogenomics of EGFR-targe ...... l lung cancer: EGFR and beyond
@en
Pharmacogenomics of EGFR-targe ...... l lung cancer: EGFR and beyond
@nl
P2860
P921
P3181
P1476
Pharmacogenomics of EGFR-targe ...... l lung cancer: EGFR and beyond
@en
P2093
Christopher Delaney
Samuel Frank
P2860
P2888
P304
P3181
P356
10.1186/S40880-015-0007-9
P407
P5008
P577
2015-04-08T00:00:00Z
P5875
P6179
1008821545